<DOC>
	<DOCNO>NCT00999622</DOCNO>
	<brief_summary>RATIONALE : Gathering information time laboratory test patient newly diagnose malignant supratentorial astrocytoma may help doctor learn effect treatment white blood cell count risk infection . PURPOSE : This clinical trial study blood sample risk infection patient newly diagnose malignant supratentorial astrocytoma .</brief_summary>
	<brief_title>Study Blood Samples Risk Infection Patients With Newly Diagnosed Malignant Supratentorial Astrocytoma</brief_title>
	<detailed_description>OBJECTIVES : - Determine frequency severity decrease CD4 count function therapy patient newly diagnose malignant astrocytoma . - Determine whether decrease CD4 count significant predictor infection adverse outcome patient . OUTLINE : This multicenter study . Patients undergo monthly collection blood serial CD4 count heme-8 differential 1 year quantitative analysis . Patients also complete monthly questionnaire infection antibiotic use . Patients follow every 2 month . PROJECTED ACCRUAL : A total 125 patient ( 100 high-grade disease 25 low-grade disease ) accrue study .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Astrocytoma</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm primary malignant brain tumor 1 follow group : High grade ( grade III IV ) supratentorial glioma receive antineoplastic treatment 1 follow histology : Anaplastic astrocytoma Glioblastoma multiforme ( giant cell glioblastoma gliosarcoma ) Anaplastic oligodendroma Low grade ( grade I II ) supratentorial glioma plan receive treatment kind ( include steroid ) 1 follow histology : Astrocytoma Oligodendroglioma PATIENT CHARACTERISTICS : Karnofsky performance status 60100 % No HIV positivity PRIOR CONCURRENT THERAPY : No prior chemotherapy brain tumor except polifeprosan 20 carmustine implant ( GliadelÂ® wafer ) No prior cranial radiotherapy radiotherapy brain tumor No prior immunotherapy biologic agent brain tumor , include follow : Immunotoxins Immunoconjugates Peptide receptor antagonist Interleukins Interferons Tumorinfiltrating lymphocyte Lymphokineactivated killer cell therapy Gene therapy Antisense therapy No prior hormonal therapy brain tumor More 14 day since prior concurrent steroid therapy patient lowgrade ( grade I II ) astrocytoma Prior glucocorticoid therapy allow</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>infection</keyword>
	<keyword>adult anaplastic astrocytoma</keyword>
	<keyword>adult anaplastic oligodendroglioma</keyword>
	<keyword>adult giant cell glioblastoma</keyword>
	<keyword>adult gliosarcoma</keyword>
	<keyword>adult oligodendroglioma</keyword>
	<keyword>adult glioblastoma</keyword>
	<keyword>adult diffuse astrocytoma</keyword>
	<keyword>adult pilocytic astrocytoma</keyword>
	<keyword>adult pineal gland astrocytoma</keyword>
	<keyword>adult subependymal giant cell astrocytoma</keyword>
</DOC>